Press Releases

Investors

Press Releases

 
Press Releases
  Date Title and Summary View
Apr 6, 2011
PASADENA, Calif. — April 6, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that majority-owned subsidiary Ablaris Therapeutics, Inc. has completed a second closing of its Series A financing round for g...
Mar 8, 2011
PASADENA, Calif. — March 8, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the Roth 23rd Annual OC Growth Stock Confe...
Feb 10, 2011
PASADENA, Calif. – February 10, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 first quarter ended December 31, 2010. “With the sale of Unidym last ...
Feb 9, 2011
PASADENA, Calif. — February 9, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the 13th Annual BIO CEO & Investor Conference at 8:00 a.m. Eastern time on Monday, February 14, 2011 at the Waldorf-Asto...
Feb 6, 2011
PASADENA, Calif. — February 4, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a focused nanomedicine holding company, today announced that it will report its financial results for the fiscal 2011 first quarter ended December 31, 2010, on Thursday, February 10, 2011 after the market closes. Arrowhead management wi...
Jan 18, 2011
PASADENA, Calif. - January 18, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Unidym, Inc. subsidiary has been acquired by Wisepower Co., Ltd., a publicly-traded, Seoul, Korea-based electronics company (KOSDAQ: 040670). Upfront consideration to Unidym shareholders consists of Wisepower stock and convertible bonds v...
Jan 8, 2011
PASADENA, Calif. – January 18, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR) (“the Company”) today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted approximately $8M of Calando debt to Arrowhead into equity. Arrowhead now owns approxima...
Page: FirstPrevious ...
22
= add release to Briefcase